BLOOD CLOTTING ACCELERANT MARKET ANALYSIS

Blood Clotting Accelerant MarketSize and Trends

The rising prevalence of hemophilia, thrombosis, pulmonary embolism, and deep vein thrombosis is resulting in increasing burden of blood clot conditions in the world. Blood clotting accelerant is an effective treatment for hemophilia and thrombosis blood clot conditions and also in surgical procedures. Thus, pharmaceutical companies across the world are focusing on research and development, to expect growth and make profit in the global blood clotting accelerant market. For instance, in July 2020, Precision Biologic Inc, a leading developer of blood clot accelerant products, announced the launch of CYROCHECK chromogenic factor VIII assay in the U.S. It will be used by clinical labs for determination of factor VIII in human plasma in case of hemophilia A.

Global Blood Clotting Accelerant Market- Impact of COVID-19

An unprecedented outbreak of the COVID-19 (coronavirus) has impacted blood clotting accelerants market negatively. As coronavirus spread in New York in late March, doctors of Mount Sinai Hospital noticed something strange happening to patient’s blood. Doctors from different specialties observed Signs of blood thickening and clotting were being detected in different organs in patient. Thus, use of blood clotting accelerants may lead to dangerous situation during this pandemic period, as thrombosis, blood cancer, and pulmonary embolism patients are at high risk of being affected by COVID-19 infection. In such cases, further administration of blood clot accelerants in patients may lead to patient fatalities. This factor is resulting in declining demand for blood clot accelerants during this pandemic situation.Global Blood Clotting Accelerant Market- Directions

Market Trends

Global
Global Blood Clotting Accelerant Market- Restraints